, Caisse nationale de l'Assurance Maladie. Consommation et dépenses de médicaments : Comparaison des pratiques françaises et européennes, pp.4-6, 2007.

E. Lir, . Santé, and G. Pouvourville, Synthèse de l'étude européenne sur la consommation de médicaments, 2012.

I. Disponible-sur,

, Utilisation des inhibiteurs de la pompe à protons (IPP) Étude observationnelle à partir des données du, SNDS. Déc, pp.9-51, 2018.

S. Duc and N. Salles, Trop d'IPP au long cours chez le sujet âgé ? La revue du praticien Médecine générale, vol.26, pp.23-25, 2012.

C. Saint-laurent, C. Cuvelier, F. Harnois, B. Loison, and G. Macaigne, Évaluation des pratiques professionnelles sur la pertinence des prescriptions des IPP dans un centre hospitalier général, 2013.

M. Villiet, L. Giraudon, C. Combescure, and S. Hansel-esteller, Bon usage des inhibiteurs de la pompe à protons : étude observationnelle des prescriptions en milieu hospitalier, Journal de Pharmacie Clinique, vol.28, pp.135-140, 2009.

F. Parente, C. Cucino, S. Gallus, S. Bargiggia, S. Greco et al., Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey, Aliment Pharmacol Ther, vol.17, issue.12, pp.1503-1506, 2003.

M. Naunton, G. M. Peterson, and M. D. Bleasel, Overuse of proton pump inhibitors, Journal of Clinical Pharmacy and Therapeutics, vol.25, issue.8, pp.333-340, 2000.

, Ministère des solidarités et de la santé

I. Disponible-sur,

, Agence Française de Sécurité Sanitaire des Produits de Santé. Recommandations de bonne pratique, les anti-sécrétoires gastriques chez l'adulte, 2007.

H. Autorité-de-santé, Médicaments inhibiteurs de la pompe à protons chez l'adulte : réévaluation. Commission de la transparence, 2009.

V. Gordon and J. Jankowski, Chemoprevention in Barrett's oesophagus. Best Practice & Research Clinical Gastroenterology, vol.25, pp.569-579, 2011.

H. Autorité-de-santé, Traitement de l'infection par Helicobacter pylori chez l'adulte. Pertinence des soins, 2017.

R. M. Martin, N. R. Dunn, S. Freemantle, and S. Shakir, The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies: Adverse events with proton pump inhibitors, British Journal of Clinical Pharmacology, vol.50, issue.4, pp.366-372, 2001.

R. A. Giannella, S. A. Broitman, and N. Zamcheck, Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro, Gut. 1 Avr, vol.13, issue.4, pp.251-256, 1972.

J. Theisen, Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids, Journal of Gastrointestinal Surgery, vol.4, issue.1, pp.50-54, 2000.

L. Lombardo, M. Foti, O. Ruggia, and A. Chiecchio, Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy, Clinical Gastroenterology and Hepatology, vol.8, issue.6, pp.504-508, 2010.

S. Dial, Proton pump inhibitor use and risk of community-acquired Clostridium difficileassociated disease defined by prescription for oral vancomycin therapy, Canadian Medical Association Journal. Sep, vol.175, issue.7, pp.745-748, 2006.

T. Chang, W. Hsu, Y. Lu, C. Hsueh, P. Chen et al., Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children, Immunology and Infection. Sep, issue.18, pp.1-7, 2018.

R. A. Hafiz, C. Wong, S. Paynter, M. David, and G. Peeters, The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Metaanalysis, Ann Pharmacother, vol.52, issue.7, pp.613-622, 2018.

K. B. Filion, D. Chateau, L. E. Targownik, G. A. Durand, M. Tamim et al., Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis, Gut. Apr, vol.63, issue.4, pp.552-558, 2014.

J. Zirk-sadowski, J. A. Masoli, J. Delgado, W. Hamilton, W. D. Strain et al., Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults: PPIs and pneumonia, J Am Geriatr Soc. Jul, vol.66, issue.7, pp.1332-1338, 2018.

C. Wang, C. Li, R. Hsieh, C. Fan, T. Hsu et al., Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies, Expert Opinion on Drug Safety. Mar, vol.18, issue.3, pp.163-172, 2019.

J. S. Bajaj, Y. Zadvornova, D. M. Heuman, M. Hafeezullah, R. G. Hoffmann et al., Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites, Am J Gastroenterol, vol.104, issue.5, pp.1130-1134, 2009.

M. Garcia-saenz-de-sicilia, PPIs are not associated with a lower incidence of portalhypertension-related bleeding in cirrhosis. WJG, vol.16, pp.5869-5873, 2010.

A. Deshpande, V. Pasupuleti, P. Thota, C. Pant, S. Mapara et al., Acidsuppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis: Acid-suppressive therapy and SBP, J Gastroenterol Hepatol, vol.28, issue.2, pp.235-242, 2013.

J. Zhu, X. Qi, H. Yu, E. M. Yoshida, N. Mendez-sanchez et al., Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis, United European Gastroenterology Journal. Oct, vol.6, issue.8, pp.1179-1187, 2018.

L. E. Targownik, A. L. Goertzen, Y. Luo, and W. D. Leslie, Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure, American Journal of Gastroenterology, vol.112, issue.1, pp.95-101, 2017.

C. Eom, S. M. Park, S. Myung, J. M. Yun, and J. Ahn, Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies. The Annals of Family Medicine, vol.9, pp.257-267, 2011.

J. R. Lam, J. L. Schneider, W. Zhao, and D. A. Corley, Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B 12 Deficiency, JAMA, vol.310, issue.22, pp.2435-2442, 2013.

J. R. Lam, J. L. Schneider, C. P. Quesenberry, and D. A. Corley, Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency, Gastroenterology, vol.152, issue.4, pp.821-829, 2017.

E. Bahtiri, H. Islami, R. Hoxha, A. Gashi, K. Thaci et al., Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study, Turk J Gastroenterol, vol.28, issue.2, pp.104-109, 2017.

W. Cheungpasitporn, C. Thongprayoon, W. Kittanamongkolchai, N. Srivali, P. J. Edmonds et al., Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies, Renal Failure, vol.37, issue.7, pp.1237-1241, 2015.

T. Cundy and J. Mackay, Proton pump inhibitors and severe hypomagnesaemia: Current Opinion in Gastroenterology, vol.27, pp.180-185, 2011.

C. F. Morschel, D. Mafra, and J. Eduardo, The relationship between proton pump inhibitors and renal disease, J Bras Nefrol, vol.40, issue.3, pp.301-306, 2018.

Y. Xie, B. Bowe, T. Li, H. Xian, Y. Yan et al., Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International, vol.91, pp.1482-1494, 2017.

W. Cheungpasitporn, C. Thongprayoon, W. Kittanamongkolchai, N. Srivali, P. J. Edmonds et al., Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies, Renal Failure, vol.37, issue.7, pp.1237-1241, 2015.

O. K. Bonderup, G. L. Nielsen, M. Dall, A. Pottegård, and J. Hallas, Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study, Aliment Pharmacol Ther. Sep, vol.48, issue.6, pp.618-625, 2018.

N. Badiola, V. Alcalde, A. Pujol, L. Münter, G. Multhaup et al., The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production. Ginsberg SD, éditeur. Plos one, vol.8, p.58837, 2013.

W. Gomm, V. Holt, K. Thomé, F. Broich, K. Maier et al., Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis, JAMA Neurol, vol.73, issue.4, pp.410-416, 2016.

M. Li, Z. Luo, S. Yu, and Z. Tang, Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine, vol.98, p.14422, 2019.

L. Rodriguez, J. Lagergren, and M. Lindblad, Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut, vol.55, pp.1538-1544, 2006.

K. S. Cheung, E. W. Chan, A. Wong, L. Chen, I. Wong et al., Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori : a population-based study, Gut, vol.67, issue.1, pp.28-35, 2018.

C. S. Jianu, R. Fossmark, T. Viset, G. Qvigstad, Ø. Sørdal et al., Gastric carcinoids after long-term use of a proton pump inhibitor, Aliment Pharmacol Ther, vol.36, issue.7, pp.644-649, 2012.

M. D. Kearns, B. Boursi, and Y. Yang, Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiology, pp.80-84, 2017.

M. Gilard, B. Arnaud, J. Cornily, L. Gal, G. Lacut et al., Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin, Journal of the American College of Cardiology, vol.51, issue.3, pp.256-260, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00684145

B. R. Disney, R. Watson, A. D. Blann, G. Lip, and M. R. Anderson, Review article: proton pump inhibitors with clopidogrel -evidence for and against a clinically-important interaction: Review: proton pump inhibitors and clopidogrel, Alimentary Pharmacology & Therapeutics, vol.33, issue.7, pp.758-767, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00613926

A. Demcsák, T. Lantos, E. R. Bálint, P. Hartmann, Á. Vincze et al., PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis, Front Physiol. Nov, vol.9, p.1550, 2018.

A. B. Lødrup, C. Reimer, and P. Bytzer, Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment, Scandinavian Journal of Gastroenterology, vol.48, issue.5, pp.515-522, 2013.

Y. Xie, B. Bowe, Y. Yan, H. Xian, T. Li et al., Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study, BMJ, 1580.

A. Pilotto, M. Franceschi, G. Leandro, C. Scarcelli, D. 'ambrosio et al., Clinical Features of Reflux Esophagitis in Older People: A Study of 840 Consecutive Patients, Journal of the American Geriatrics Society, vol.54, issue.10, pp.1537-1542, 2006.

J. C. Létard, S. Bruley-des-varannes, and V. Costil, Société Nationale Française de Gastro-Entérologie, 2017.

I. Disponible-sur,

D. A. Drossman, Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV, Gastroenterology, vol.150, issue.6, pp.1262-1279, 2016.

L. E. Targownik, C. J. Metge, and S. Laung, Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications, Aliment Pharmacol and Ther, pp.88-96, 2008.

S. K. Murthy, S. Kauldher, and E. Targownik, Physicians' approaches to the use of gastroprotective strategies in low-risk non steroidal anti-inflammatory drugs users, Aliment Pharmacol and Ther, pp.1365-1372, 2006.

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonoré et méprisé si j'y manque